Navigation Links
arGEN-X Announces Non-Exclusive License With BioWa for POTELLIGENT® Technology
Date:7/26/2011

ROTTERDAM, Netherlands, GHENT, Belgium, and PRINCETON, N.J., July 26, 2011 /PRNewswire/ -- arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announces it has signed a non-exclusive license agreement with BioWa Inc., the exclusive worldwide licensor of POTELLIGENT® Technology.

arGEN-X's SIMPLE Antibody™ platform is unique in providing human variable regions of unprecedented diversity, allowing the rapid selection of antibodies with superb functional potency. In under two years, these attributes have already been validated preclinically in seven in vivo and ex vivo models, highlighting the productivity of the technology.

POTELLIGENT® Technology is a clinically validated approach to producing monoclonal antibodies (mAbs) with significantly enhanced antibody-dependent cellular cytotoxicity (ADCC) and tumor cell killing activity. By combining the power of the SIMPLE Antibody™ platform with POTELLIGENT® Technology, arGEN-X expects to increase the intrinsic potency of these mAbs even further. Under this license agreement, arGEN-X will apply POTELLIGENT® Technology to its own novel mAbs addressing cancer and inflammatory disorders and will offer antibodies encompassing both technologies to its commercial partners.

Commenting on today's announcement, Tim Van Hauwermeiren, CEO of arGEN-X, said: "We are applying our proprietary SIMPLE Antibody™ technology to targets where a selectively potent antibody interaction works in concert with effector function to mediate optimal therapeutic effects. The extraordinary diversity of antibodies generated from our platform allows us to preferentially select leads with only the highest quality functional properties. Combining such superior variable regions with constant regions enhanced by the validated POTELLIGENT® Technology supports our
'/>"/>

SOURCE BioWa, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. arGEN-X Granted Broad Patent Covering its Unique SIMPLE Antibody(TM) Platform
2. arGEN-X SIMPLE Antibody(TM) Platform set to Transform Therapeutic Antibody Discovery & Development
3. arGEN-X Concludes EUR 12.5 Million Series A Financing Round
4. NuMe Health Announces Closing of Series A-1 Financing Round
5. Amgen Announces Webcast of 2011 Second Quarter Financial Results
6. Lanx, Inc. Announces Aspen™ Spinous Process Fixation System Clinical Data at IMAST
7. Prasco® Announces Authorized Generic Agreement with Shionogi Inc.
8. Cornerstone Pharmaceuticals Announces The Journal of Molecular Medicines Publication of Research Showing Selective Inhibition of Cancer Cell Energy Metabolism With Its Novel Lipoate Derivative Compounds
9. SurgiCount Medical Announces Expanded Honor Roll Hospital Users, Landmark Product Usage Milestones Achieved
10. Valeant Pharmaceuticals Announces Approval of Sublinox® in Canada
11. Taiho Pharmaceutical Announces Results of Randomized Phase II Clinical Trial with Novel Antitumor Agent TAS-102
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... SAN DIEGO , March 27, 2015 /PRNewswire/ ... informatics company, today announced new data showing that, ... Mantis TM technology provided highly equivalent interpretations ... cause disease, and did so in a fraction ... pave the way for more comprehensive genetic analysis ...
(Date:3/27/2015)... 27, 2015 XRpro Sciences, Inc., a ... and development services which features high throughput transporter ... announced financial results for the year ended December ... Chairman of XRpro Sciences commented, "We have completed ... development stage to commercial stage in large part ...
(Date:3/27/2015)... According to a new market research report ... Ablation Catheter (Cryoablation, RF, Microwave), Lab Devices (Mapping, Recording, ... Global Forecasts to 2019 ", published by MarketsandMarkets, the Electrophysiology ... by 2019 with a CAGR of around 10.3% during ... Browse   90   ma rket data T ...
Breaking Medicine Technology:New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 3XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4
... Md., Dec. 13, 2011 Vanda Pharmaceuticals Inc. (Vanda) ... on the development and commercialization of products for central ... with Megapharm Ltd., one of Israel,s leading private biotech, ... of Fanapt™  in Israel. "We are excited ...
... VIEW, Calif., Dec. 13, 2011 Alexza Pharmaceuticals, Inc. ... Psychopharmacologic Drugs Advisory Committee (PDAC) of the U.S. Food ... (Staccato® loxapine) be approved for use as a single ... recommended Risk Evaluation and Mitigation Strategy (REMS), for the ...
Cached Medicine Technology:Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 2Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 3Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 4FDA Psychopharmacologic Drugs Advisory Committee Recommends Approval of Alexza's ADASUVE™ 2FDA Psychopharmacologic Drugs Advisory Committee Recommends Approval of Alexza's ADASUVE™ 3FDA Psychopharmacologic Drugs Advisory Committee Recommends Approval of Alexza's ADASUVE™ 4FDA Psychopharmacologic Drugs Advisory Committee Recommends Approval of Alexza's ADASUVE™ 5
(Date:3/28/2015)... "Necrorun" was featured on NewsWatch as part of its ... and coolest applications on the market for iOS, Android, ... technology expert, conducted the app review and shared with ... with knights, nature, and peasants. , The first ... Eurogamer. The popularity of these games grew over the ...
(Date:3/28/2015)... Emergency Medical Care (EMC), a New ... recently commemorated its three-year anniversary of being the only ... to 24-hour urgent care, Emergency Medical Care offers its ... time, Emergency Medical Care’s Urgent Care NYC ... eye injuries, ear infections, fevers, insect bites, burns, animal ...
(Date:3/28/2015)... March 28, 2015 One in three ... to research presented today at the American Orthopaedic Society ... study examined the long term success of surgery for ... examined survey data from 242 patients who underwent ACL ... P. Roe, MBBS, FRACS, from North Sydney Orthopaedic and ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Andrew Hawley of ... 1960's Who psychedelic concert posters. The Who and the Doors ... on August 2, 1968. According to Hawley, “The Who toured ... concert halls and college campuses. Perhaps the most famous Who ... Jim Morrison and the Doors on August 2, 1968 at ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Designers and ... new overlay entitled Scratches 5K from Pixel Film Studios. ... effects to any media inside Final Cut Pro X” ... Corporate saves time and is an effective tool for ... FCPX Overlay Scratches 5K's intuitive grunge overlays. Simply drag ...
Breaking Medicine News(10 mins):Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2
... Practitioners of clinical medicine are familiar with learning ... minimize learning-curve effects on clinical care. Because similar learning ... researchers at Duke University Medical Center studied the phenomenon ... trial. Their findings point to ways to improve the ...
... Researchers seeking to learn more about stroke by studying ... this week releasing new findings that they hope will aid ... cancer. The Japanese team is reporting in a ... that they are optimistic that inhibiting a protein found on ...
... of prostate cell that has been largely ignored by cancer ... new studies by Howard Hughes Medical Institute (HHMI) scientists and ... his colleagues at the University of California, Los Angeles (UCLA) ... tumors in the prostate gland. Their studies, which were unveiled ...
... would assume that body-checking -- intentionally slamming an opponent against ... hockey. But they would be wrong. Findings from a ... of young hockey players, show that 66 percent of overall ... posts, colliding with teammates or being hit by a puck. ...
... The recent discovery of more than a thousand genes ... up a new approach to understanding the function and ... made even more compelling with the finding that dozens ... commonly mutated gene in cancer), suggesting that this class ...
... history of male breast cancer perceive themselves to be at ... a family history of female breast cancer; however those with ... know about or seek genetic testing than those with a ... led by researchers at the University of Louisville,s James Graham ...
Cached Medicine News:Health News:Clinical trials can be improved by managing the learning curve 2Health News:Clinical trials can be improved by managing the learning curve 3Health News:Snake venom studies yield insights for development of therapies for heart disease and cancer 2Health News:Snake venom studies yield insights for development of therapies for heart disease and cancer 3Health News:Snake venom studies yield insights for development of therapies for heart disease and cancer 4Health News:A new ground zero for prostate cancer 2Health News:A new ground zero for prostate cancer 3Health News:Most youth hockey injuries caused by accidents, not checking, UB study shows 2Health News:'Linc-ing' a noncoding RNA to a central cellular pathway 2Health News:Male breast cancer in family leads to high perception of risk, low likelihood of genetic counseling 2Health News:Male breast cancer in family leads to high perception of risk, low likelihood of genetic counseling 3
Inquire...
Inquire...
... anti-reflux valve is enclosed in ... prevents the valve from being ... sitting or reclining positions. The ... interference free ensuring uninterrupted flow ...
... valve is enclosed in a ... the valve from being accidentally ... or reclining positions. The valve ... free ensuring uninterrupted flow and ...
Medicine Products: